CA-CYOLO
26.3.2024 13:31:29 CET | Business Wire | Press release
Cyolo, the access company for the industrial enterprise, today announced a new partnership with TD SYNNEX, a leading global distributor and solutions aggregator for the IT ecosystem. The powerful combination of TD SYNNEX’s solution aggregation capabilities and Cyolo’s highly disruptive, distributed secure remote access platform will lead partners to new service lines of revenue. The partnership empowers TD SYNNEX and Cyolo partners to tap into the increased enterprise demand of Secure Remote Access in operational technology (OT), critical infrastructure, cyber physical environments, and their corresponding buying centers.
The partnership with TD SYNNEX serves as the cornerstone of the Cyolo PRO (Privilege Remote Operations) launch. The recently launched Cyolo PRO Platform allows service providers, integrators, OT, IT personnel and other third parties to securely access and safely operate applications, devices and systems in the most critical environments. Cyolo PRO takes secure remote access to new levels with its distributed architecture and its converged security stack capabilities. Cyolo is cloud routed and cloud managed without being cloud hosted. Unlike current technologies such as VPN and SASE that provide users with full access to the network, Cyolo PRO enables secure and privileged access by connecting robustly verified identities to applications with persistent authorization.
“The strategic nature of our TD SYNNEX relationship is a pivotal step in realizing our commitment to delivering future-ready, safe and secure privilege access solutions to the massive industrial market,” said Cyolo’s EVP Corporate Development and OT GM Joe O’Donnell. “Through this collaboration, TD SYNNEX’s partners can bring Cyolo PRO to a broader range of OT, IT and Cyber Physical stakeholders. This increases safety, security and accelerates operational agility. The solution’s capability to seamlessly fit into existing architectures without extensive change management processes is critical in OT environments, as even the slightest network and security change can yield significant consequences.”
This global partnership enables thousands of TD SYNNEX integrators, VARs, MSSPs and Carriers to provide next generation SRA/RPAM (Remote Privilege Access Management) services to their respective customers. Cyolo PRO enables TD SYNNEX partners to address the fast-growing OT and Cyber Physical markets by focusing on crucial elements that increase their clients’ operational agility, improves customers’ security and providing safe yet swift implementations with the lowest cost of change.
"TD SYNNEX is committed to uniting IT solutions that deliver business outcomes today and unlock growth for the future," said Cheryl Day, VP Vendor Acquisition and Global Solutions at TD SYNNEX. "With Cyolo added to our vast portfolio of vendor partners, we're able to enrich the breadth and depth of our offerings so customers can do great things with technology."
To learn more about Cyolo PRO, please visit: https://cyolo.io/product
About Cyolo
Cyolo replaces current SRA implementations with next gen privileged remote operations by connecting verified identities directly to applications with continuous authorization throughout the connection. Purpose-built for deployment in every type of environment, Cyolo PRO combines multiple Remote Privilege Access Management (RPAM) security functions required to mitigate high-risk access, including zero-trust access for users and devices, MFA for the last mile, IdP capabilities, credentials vault, secure file transfer, supervised access, session recording, and much more into a single, cost-effective, easy-to-deploy, and user-friendly platform. For more information visit cyolo.io or follow us on LinkedIn and X.
About TD SYNNEX
TD SYNNEX (NYSE: SNX) is a leading global distributor and solutions aggregator for the IT ecosystem. We’re an innovative partner helping more than 150,000 customers in 100+ countries to maximize the value of technology investments, demonstrate business outcomes and unlock growth opportunities. Headquartered in Clearwater, Florida, and Fremont, California, TD SYNNEX’s 23,000 co-workers are dedicated to uniting compelling IT products, services and solutions from 2,500+ best-in-class technology vendors. Our edge-to-cloud portfolio is anchored in some of the highest-growth technology segments including cloud, cybersecurity, big data/analytics, AI, IoT, mobility and everything as a service. TD SYNNEX is committed to serving customers and communities, and we believe we can have a positive impact on our people and our planet, intentionally acting as a respected corporate citizen. We aspire to be a diverse and inclusive employer of choice for talent across the IT ecosystem. For more information, visit www.TDSYNNEX.com, follow our newsroom or follow us on LinkedIn, Facebook and Instagram.
Copyright 2024 TD SYNNEX Corporation. All rights reserved. TD SYNNEX, the TD SYNNEX Logo, and all other TD SYNNEX company, product and services names and slogans are trademarks of TD SYNNEX Corporation. Other names and trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326860005/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom